Place open oncology protocols directly in front of verified oncology clinicians, research coordinators, and informed patient advocates — the exact professionals and patients already searching for trial options. Featured placements, newsletter spotlights, and protocol pages built for accrual.
Visitors to KCLEAGENICS MEDICAL are already in a clinical trial mindset. They're reading protocol summaries, checking eligibility criteria, and looking for options — not browsing passively. A featured placement here means your trial appears at the exact moment a clinician or patient is actively considering their next step.
Unlike general oncology media or pharma news publications, this audience is granular: oncology subspecialty professionals and patients with specific tumour types, biomarker profiles, and prior treatment histories — the variables your protocol cares about most.
Placements are built around your specific open protocol — tumour type, phase, key eligibility — not general brand awareness. Clinicians see exactly what their patients may qualify for.
Our monthly Clinical Intelligence Briefing goes to a subscriber list of oncology professionals and informed patients. Newsletter features are exclusive — one sponsor per issue.
Dedicated protocol pages are optimised for oncology-specific search queries — increasing organic discoverability alongside the direct placement visibility.
All placements include a monthly report: page views, click-throughs to your trial page, pre-screening form completions, and referral leads generated.
All placements are protocol-specific and campaign-based. Rates are quoted on enquiry based on therapeutic area, campaign duration, and placement combination.
Dedicated section in the monthly Clinical Intelligence Briefing, sent to our oncology professional and patient subscriber list.
Featured protocol listing on the homepage and relevant condition pages, with a dedicated trial listing page built and indexed.
A sponsored editorial article on the KCLEAGENICS MEDICAL blog — clinical context, rationale, and eligibility — written to inform and refer.
A randomised, open-label Phase II study evaluating [investigational agent] versus docetaxel in patients with previously treated KRAS G12C-mutant NSCLC. Sites actively enrolling in the US Midwest and Southeast.
Example only. Sponsor branding, trial name, and eligibility details are replaced with your protocol's information.
Tell us your protocol, therapeutic area, and which placement(s) you're considering. We'll respond within one business day.
We'll confirm availability, provide a flat-rate quote, and agree a campaign start date. No lengthy negotiation.
Share your ClinicalTrials.gov number, key I/E criteria, and preferred referral contact. We handle the writing and formatting.
Your placement goes live within 5 business days. Monthly reports cover views, referral enquiries, and pre-screen completions.
Tell us your protocol and what you're trying to achieve — tumour type, phase, how many sites are currently recruiting, and whether enrolment is behind pace. We'll respond with available placement slots, rates, and an example placement for your therapeutic area.
All enquiries are confidential. We do not share protocol details or sponsor identity with third parties without explicit permission.
Prefer to talk first?
All sponsored content and featured placements are clearly labelled as such. KCLEAGENICS MEDICAL does not accept placements for protocols that are not registered on ClinicalTrials.gov, and does not publish clinical claims that are not supported by the registered protocol or published data. Sponsored articles are written by the KCLEAGENICS MEDICAL editorial team and subject to our standard clinical accuracy review. We reserve the right to decline any placement that conflicts with our editorial standards.